CD8A and familial pancreatic carcinoma: On the other hand, it also reveals that CD8+ T cell-based immunotherapy may be effective in pancreatic cancer; interfering with the immune microenvironment of the tumour through miRNA may be an effective means to improve the prognosis of pancreatic cancer.